Outbreak of Adverse Reactions Associated with Contaminated Heparin

David B. Blossom(Epidemic Intelligence Service), Alexander J. Kallen(Epidemic Intelligence Service), Priti R. Patel, Alexis Elward(St. Louis Children's Hospital), Luke N. Robinson, Gan‐Pan Gao, Róbert Langer(Harvard–MIT Division of Health Sciences and Technology), Kiran M. Perkins, Jennifer L. Jaeger(Epidemic Intelligence Service), Katie Kurkjian(Epidemic Intelligence Service), Marilyn C. Jones(BJC HealthCare), Sarah Schillie(Epidemic Intelligence Service), Nadine Shehab, Daniel Ketterer, Ganesh Venkataraman(Momenta Pharmaceuticals (United States)), Takashi Kishimoto(Momenta Pharmaceuticals (United States)), Zachary Shriver(Momenta Pharmaceuticals (United States)), Ann McMahon(Center for Drug Evaluation and Research), K. Frank Austen(Brigham and Women's Hospital), Steven Kozlowski(Center for Drug Evaluation and Research), Arjun Srinivasan, George Turabelidze(Missouri Department of Health and Senior Services), Carolyn V. Gould, Matthew J. Arduino, Ram Sasisekharan(Harvard–MIT Division of Health Sciences and Technology)
New England Journal of Medicine
December 4, 2008
Cited by 280Open Access
Full Text

Abstract

BACKGROUND: In January 2008, the Centers for Disease Control and Prevention began a nationwide investigation of severe adverse reactions that were first detected in a single hemodialysis facility. Preliminary findings suggested that heparin was a possible cause of the reactions. METHODS: Information on clinical manifestations and on exposure was collected for patients who had signs and symptoms that were consistent with an allergic-type reaction after November 1, 2007. Twenty-one dialysis facilities that reported reactions and 23 facilities that reported no reactions were included in a case-control study to identify facility-level risk factors. Unopened heparin vials from facilities that reported reactions were tested for contaminants. RESULTS: A total of 152 adverse reactions associated with heparin were identified in 113 patients from 13 states from November 19, 2007, through January 31, 2008. The use of heparin manufactured by Baxter Healthcare was the factor most strongly associated with reactions (present in 100.0% of case facilities vs. 4.3% of control facilities, P<0.001). Vials of heparin manufactured by Baxter from facilities that reported reactions contained a contaminant identified as oversulfated chondroitin sulfate (OSCS). Adverse reactions to the OSCS-contaminated heparin were often characterized by hypotension, nausea, and shortness of breath occurring within 30 minutes after administration. Of 130 reactions for which information on the heparin lot was available, 128 (98.5%) occurred in a facility that had OSCS-contaminated heparin on the premises. Of 54 reactions for which the lot number of administered heparin was known, 52 (96.3%) occurred after the administration of OSCS-contaminated heparin. CONCLUSIONS: Heparin contaminated with OSCS was epidemiologically linked to adverse reactions in this nationwide outbreak. The reported clinical features of many of the cases further support the conclusion that contamination of heparin with OSCS was the cause of the outbreak.


Related Papers

No related papers found

Powered by citation graph analysis